Newron Pharmaceuticals S.p.A.

As of December 31, 2025, Newron Pharmaceuticals S.p.A. carries a market capitalization of 488.98M, placing it among publicly traded companies globally. Its enterprise value stands at 497.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Newron Pharmaceuticals S.p.A.'s next confirmed earnings release is scheduled for March 16, 2027.

As of December 31, 2025, Newron Pharmaceuticals S.p.A. has 20.01M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Newron Pharmaceuticals S.p.A. maintains a current ratio of 0.76, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Newron Pharmaceuticals S.p.A.'s stock has declined approximately 40.29% over the past 52 weeks. The 50-day moving average sits at 10.48, while the 200-day moving average is 14.71.

As of December 31, 2025, Newron Pharmaceuticals S.p.A. holds 26.88M in cash and equivalents against 35.53M in total debt, resulting in a net debt position of 23.53M. Total book value stands at -10.37M, with working capital of -11.22M providing operational flexibility.